Home Online Features Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer’s Disease Patients in Phase 3b study
Press Releases
Eli Lilly and Company, Clinical Trials on Alzheimer's Disease  
October 29, 2024

Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer’s Disease Patients in Phase 3b study

A change in the initiation of donanemab dosing, shifting one vial of donanemab from the first infusion to the third infusion, lowered ARIA-E to 14% compared to 24% in patients

logo salamanca press

Salamanca Press

email salamanca press
Local & Social